Benitec Biopharma Inc. (BNTC)
BNTC moved a median of 0.00% 30 minutes after news, and +0.52% by the close. How BNTC actually reacts to news — the realized, point-in-time move the market made, measured across 203 labeled events over the last three years with zero look-ahead.
BNTC’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 27% | 174 |
| 30-min | 0.00% | 48% | 194 |
| 60-min | +0.39% | 54% | 199 |
| to close | +0.52% | 55% | 203 |
| Middle 50% of BNTC reactions | -1.43% to +2.34% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 203 |
Half of all Benitec Biopharma Inc. news events land between -1.43% and +2.34% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How BNTC reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 26 | -0.74% | 35% | -2.38% |
| Rating reiterations | 34 | 0.00% | 35% | -0.27% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how BNTC ranks against every other measured name →
That’s how BNTC usually reacts — get an email when it moves on news →Email me when BNTC moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to BNTC's baseline. Nothing else.
Recent BNTC events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Benitec Biopharma Announces Regulatory Update Following Type C Meeting with FDA for BB-301 Pivotal Study | Press release | GlobeNewswire | -1.28% | +2.56% | |
| Form 8-K Benitec Biopharma Inc. For: Oct 05 | SEC filing · Form 8-K | SEC EDGAR | -1.28% | +2.56% | |
| Form 8-K Benitec Biopharma Inc. For: Sep 29 | SEC filing · Form 8-K | SEC EDGAR | +0.55% | -3.62% | |
| Form 8-K Benitec Biopharma Inc. For: Sep 18 | SEC filing · Form 8-K | SEC EDGAR | -0.77% | -1.13% | |
| Form 10-K Benitec Biopharma Inc. For: Jun 30 | SEC filing · Form 10-K | SEC EDGAR | +3.66% | -9.98% | |
| Form EFFECT Benitec Biopharma Inc. | SEC filing · Form EFFECT | SEC EDGAR | +0.00% | -0.18% | |
| Benitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational Update | Press release | GlobeNewswire | +0.00% | -8.75% | |
| Form 10-K Benitec Biopharma Inc. For: Jun 30 | SEC filing · Form 10-K | SEC EDGAR | +0.00% | -8.75% | |
| Form 8-K Benitec Biopharma Inc. For: Sep 14 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -8.75% | |
| Form S-3 Benitec Biopharma Inc. | SEC filing · Form S-3 | SEC EDGAR | +0.00% | -8.75% | |
| Form 8-K Benitec Biopharma Inc. For: May 22 | SEC filing · Form 8-K | SEC EDGAR | +0.71% | -4.42% | |
| Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update | Press release | GlobeNewswire | +0.00% | +2.60% | |
| Form 10-Q Benitec Biopharma Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | +2.60% | |
| Form 8-K Benitec Biopharma Inc. For: May 14 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +2.60% | |
| Benitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meeting | Press release | GlobeNewswire | +0.00% | -3.26% | |
| Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors | Press release | Business Wire | +2.61% | +3.02% | |
| Form 10-K/A Benitec Biopharma Inc. For: Jun 30 | SEC filing · Form 10-K | SEC EDGAR | +0.89% | -0.53% | |
| Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for Oc | Press release | GlobeNewswire | +2.52% | -1.92% | |
| Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference | Press release | GlobeNewswire | +7.05% | +10.67% | |
| Benitec Biopharma Announces Acceptance of Late- Breaking Abstract for the BB-301 Phase 1b/2a Clinical Treatment Study at the Muscular Dystrophy Association Clinical & Scientific Conference | Press release | GlobeNewswire | +0.00% | +0.56% | |
| Benitec Biopharma Releases Second Quarter 2026 Financial Results and Provides Operational Update | Press release | GlobeNewswire | +0.00% | -2.99% | |
| Form 10-Q Benitec Biopharma Inc. For: Dec 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -2.99% | |
| Form 8-K Benitec Biopharma Inc. For: Feb 12 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -2.99% | |
| Form EFFECT Benitec Biopharma Inc. | SEC filing · Form EFFECT | SEC EDGAR | +0.00% | -0.60% | |
| Form S-3 Benitec Biopharma Inc. | SEC filing · Form S-3 | SEC EDGAR | +1.91% | +3.66% | |
| Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response | Press release | GlobeNewswire | -1.33% | +1.25% | |
| Form 8-K Benitec Biopharma Inc. For: Dec 01 | SEC filing · Form 8-K | SEC EDGAR | -0.77% | +7.16% | |
| Benitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational Update | Press release | GlobeNewswire | -2.55% | +1.65% | |
| Form 10-Q Benitec Biopharma Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -2.55% | +1.65% | |
| Form 8-K Benitec Biopharma Inc. For: Nov 14 | SEC filing · Form 8-K | SEC EDGAR | -2.55% | +1.65% | |
| Form DEFA14A Benitec Biopharma Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +1.47% | -0.44% | |
| Form 8-K Benitec Biopharma Inc. For: Nov 05 | SEC filing · Form 8-K | SEC EDGAR | -0.51% | +7.75% | |
| Benitec Biopharma Inc. Announces Pricing of $100 Million Common Stock Offering | Press release | GlobeNewswire | -0.99% | -8.81% | |
| Benitec Biopharma Inc. Announces Proposed Public Offering | Press release | GlobeNewswire | -0.99% | -8.81% | |
| Benitec Biopharma Announces Appointment of Sharon Mates Ph.D. to its Board of Directors | Press release | GlobeNewswire | +11.92% | +20.43% | |
| Benitec Biopharma Provides Positive Interim Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial and Receives FDA Fast Track Designation for BB-301 | Press release | GlobeNewswire | +11.92% | +20.43% | |
| Form 8-K Benitec Biopharma Inc. For: Nov 02 | SEC filing · Form 8-K | SEC EDGAR | +11.92% | +20.43% | |
| Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy | Press release | GlobeNewswire | +11.92% | +20.43% | |
| Form DEF 14A Benitec Biopharma Inc. For: Dec 01 | SEC filing · Form DEF | SEC EDGAR | -3.24% | +5.44% | |
| Form DEFA14A Benitec Biopharma Inc. | SEC filing · Form DEFA14A | SEC EDGAR | -3.24% | +5.44% | |
| Form EFFECT Benitec Biopharma Inc. | SEC filing · Form EFFECT | SEC EDGAR | +0.00% | +0.50% | |
| Benitec Biopharma Releases Full Year 2025 Financial Results and Provides Operational Update | Press release | GlobeNewswire | +0.00% | -1.05% | |
| Form 10-K Benitec Biopharma Inc. For: Jun 30 | SEC filing · Form 10-K | SEC EDGAR | +0.00% | -1.05% | |
| Form 8-K Benitec Biopharma Inc. For: Sep 22 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -1.05% | |
| Form S-3 Benitec Biopharma Inc. | SEC filing · Form S-3 | SEC EDGAR | +0.00% | -1.05% | |
| Form 8-K Benitec Biopharma Inc. For: Sep 10 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -0.72% | |
| Benitec Biopharma Provides Operational Updates | Press release | GlobeNewswire | +0.00% | +6.63% | |
| Form 8-K Benitec Biopharma Inc. For: Jul 09 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -0.51% | |
| Form EFFECT Benitec Biopharma Inc. | SEC filing · Form EFFECT | SEC EDGAR | +0.00% | +0.39% | |
| Form S-3 Benitec Biopharma Inc. | SEC filing · Form S-3 | SEC EDGAR | +0.00% | +8.48% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the BNTC section they belong to.
Where else BNTC is measured.
BNTC earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| OptiNose, Inc. (OPTN) | 205 | 0.00% | 48% |
| ASPEN PHARMACRE HL UN/ADR (APNHY) | 204 | 0.00% | 15% |
| Immuron Limited - American Depositary Shares (IMRN) | 202 | -0.21% | 29% |
| InfuSystems Holdings, Inc. (INFU) | 202 | 0.00% | 50% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Benitec Biopharma Inc.'s median reaction calculated?
Every labeled BNTC news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 203 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 48% of BNTC's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does BNTC's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.